Gazette.govt.nzPursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines which were referred to the Minister of Health under the provisions of section 24(5) of the Act and are set out in the Schedule hereto:
Schedule
| Product: | Metalyse |
| Active Ingredient: | Tenecteplase 40mg |
| Dosage Form: | Powder for injection with diluent |
| New Zealand Sponsor: | Boehringer Ingelheim (NZ) Limited |
| Manufacturer: | Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, Germany |
| Product: | Metalyse |
| Active Ingredient: | Tenecteplase 50mg |
| Dosage Form: | Powder for injection with diluent |
| New Zealand Sponsor: | Boehringer Ingelheim (NZ) Limited |
| Manufacturer: | Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, Germany |
| Product: | Perjeta |
| Active Ingredient: | Pertuzumab 30mg/mL |
| Dosage Form: | Concentrate for infusion |
| New Zealand Sponsor: | Roche Products (NZ) Limited |
| Manufacturers: | Roche Diagnostics GmbH, Mannheim, Germany Genentech Inc, Oregon, United States of America |
Dated this 5th day of June 2024.
CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).